Jazz Pharmaceuticals Reports Q3 2023 Revenue of $972M, Raises Full-Year Guidance

Jazz Pharmaceuticals plc

2023-Q3 EPS reported $4.67 revenue$2,822,269,000

Xywav net product sales grew 30% year-over-year to $331.6M; total oxybate revenue annualizing at $1.9B
Epidiolex net product sales up 9% to $213.7M; Rylaze up 43% to $104.9M
Company raises 2023 total revenue guidance to $3.75-$3.875B and oncology guidance to $975M-$1.05B
Plan to initiate zanidatamab rolling BLA submission this year for accelerated approval in 2L biliary tract cancers
GAAP net income of $146.8M vs. loss of $19.6M in Q3 2022; non-GAAP adjusted net income $340.1M

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Jazz Pharmaceuticals plc updated its the quarter ended September 30, 2023 guidance (raised).

Period: the quarter ended September 30, 2023
Guidance: raised
Result: reported results

Exact text from the filing

On November 8, 2023, Jazz Pharmaceuticals plc (the “Company”) issued a press release (the “Press Release”) announcing financial results for the Company for the quarter ended September 30, 2023.

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

Jazz Pharmaceuticals plc filing history →

Source: SEC EDGAR

accession 0001232524-23-000051

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.